MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?

Glioblastomas are the most malignant gliomas with median survival times of only 15 months despite modern therapies. All standard treatments are palliative. Pathogenetic factors are diverse, hence, stratified treatment plans are warranted considering the molecular heterogeneity among these tumors. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Hau, Peter, Stupp, Roger, Hegi, Monika E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2007
Materias:
Other
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851641/
https://www.ncbi.nlm.nih.gov/pubmed/17325429
http://dx.doi.org/10.1155/2007/159242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851641/
https://www.ncbi.nlm.nih.gov/pubmed/17325429
http://dx.doi.org/10.1155/2007/159242

Ejemplares similares